Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Forty Seven Inc (Forty Seven), formerly CD47 Sciences Inc is a clinical-stage immuno-oncology company that focuses on the development of therapies to treat cancer. The company’s lead molecule Hu5F9-G4 is a monoclonal antibody that is used against the CD47 receptor. Its monoclonal antibody is evaluated in four phase 1 clinical studies in patients with solid tumors or cutaneous T-cell lymphoma, acute myeloid leukemia, non-Hodgkin’s lymphoma, myelodysplastic syndrome and colorectal carcinoma across the US and the UK. The company partners with biotechnology and pharmaceutical companies. Forty Seven is headquartered in Menlo Park, California, the US.
Forty Seven Inc premium industry data and analytics
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer